[go: up one dir, main page]

WO2013114165A1 - Process of obtaining glycoprotein composition with increased afucosylation content - Google Patents

Process of obtaining glycoprotein composition with increased afucosylation content Download PDF

Info

Publication number
WO2013114165A1
WO2013114165A1 PCT/IB2012/057091 IB2012057091W WO2013114165A1 WO 2013114165 A1 WO2013114165 A1 WO 2013114165A1 IB 2012057091 W IB2012057091 W IB 2012057091W WO 2013114165 A1 WO2013114165 A1 WO 2013114165A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
temperature
glycoprotein
process according
vol
Prior art date
Application number
PCT/IB2012/057091
Other languages
French (fr)
Inventor
Satakarni MAKKAPATI
Vaibhav S NIKAM
Satyam Subrahmanyam
Original Assignee
Dr Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddy's Laboratories Limited filed Critical Dr Reddy's Laboratories Limited
Publication of WO2013114165A1 publication Critical patent/WO2013114165A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Definitions

  • the invention describes a method for production of glycoprotein with increased afucosylation content. More specifically, the invention describes a cell culture process wherein cells are cultured in a medium supplemented with galactose, at a specific osmolality, and harvested on about 12 th day or at about 50% viability to obtain glycoform composition with enhanced afucosylation.
  • Protein glycosylation is one of the most important post-translation
  • N-linked glycosylation in which glycans are attached to the asparagine of the recognition sequence Asn-X-Thr/Ser, where "X" is any amino acid except proline
  • O-linked glycosylation in which glycans are attached to serine or threonine
  • N-linked glycans further are of two types - high mannose type consisting of two N-acetylglucosamines plus a large number of mannose residues (more than 4), and the complex type that contain more than two N-acetylglucosamines plus any number of other types of sugars.
  • N-linked glycosylation begins co-translationally in the endoplasmic reticulum (ER) where a complex set of reactions result in the attachment of Glc 3 NAc 2 Man 9 (3 glucose, 2 N-acetylglucosamine and 9 mannose) to a carrier molecule called dolichol, and that is then transferred to the appropriate position (Asn297) on the polypeptide chain (Schwarz F. and Aebi M., Current Opinion in Structural Biology, 2011, Vol.21, Issue 5, pages 576 to 582 and Burda P., and Aebi M.,Biochemica et Biophysica acta (BBA) General Subjects, 1999, Volume 1426, Issue 2, pages 239 to 257).
  • the glycan complex formed in the ER lumen is further modified by action of enzymes in the Golgi apparatus. If the saccharide is relatively inaccessible, it is likely to remain in the original high-mannose form. If it is accessible, then several mannose residues may be cleaved and the saccharide further modified, resulting in the complex type N-glycans structure.
  • mannosidase-1 may act to cleave/hydrolyzes a high mannose glycan, while further on,fucosyltransferase FUT- 8 fucosylates the glycan in the medial-Go ⁇ g ⁇ (Harue Imai-Nishiya et al, BMC Biotechnology, 2007, 7:84).
  • sugar composition as well as the structural configuration of a glycan structure depends on the protein being glycosylated, the cells/cell lines, the glycosylation machinery in the Endoplasmic Reticulum and the Golgi apparatus, the accessibility of the machinery enzymes to the glycan structure, the order of action of each enzyme and the stage at which the protein is released from the
  • external factors may also affect the glycan structure and composition of a protein. These include the conditions in which the cell line expressing the protein is cultured, such as the medium composition, the composition and timing of the feed, osmolality, pH, temperature etc. There is a significant variability observed in terminal galactosylation that is dependent on the medium. It has been shown that feeding cultures with galactose up to a concentration 36mM results in high levels of galactosylation (Davies, J.; Jiang, L.; Pan, L.Z.; LaBarre, M. J.; Anderson, D.; Reff, M. Biotechnol.Bioeng.
  • reducing temperature can increase overall protein production by prolonging cell viability, which should, in principle, improve glycosylation (Moore A, Mercer J, Dutina G, Donahue CJ, Bauer KD,Mather JP, Etchverry T, Ryll T. Cytotechnology, 1997, Vol.23, pages 47 to 54).
  • Borys et al has shown that a deviation from optimum pH results in decrease in the expression rate as well as the extent of glycosylation of proteins ⁇ Borys M.C., Linzer, D.I.H., Papoutsakis 1993, ⁇ /technology, Vol.1 ⁇ , pages 720 to 724).
  • the culture pH of a hybridoma cell line has been shown to affect the resulting galactosylation and sialylation of the monoclonal antibody (Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter- Katalinic J., Biotechnol Bioeng. 2003, Vol.83, Issue 3, pages 321 to 334).
  • rMAb therapeutic monoclonal antibodies
  • ADCC antibody-dependent cellular cytotoxicity
  • CDC complement-dependent cytotoxicity
  • Fucose-deficient IgGI s have shown a significant enhancement of ADCC up to 100-fold (Mori K., Cytotechnology, 2007, Vol. 55(2-3), pages 109 to 114& Shields RL, The Journal of Biological Chemistry, 2002, Vol. 277(30), pages 26733to 26740).
  • non-fucosylated antibodies may be the promising next- generation therapeutic antibodies with improved efficacy and reduced dose based toxicities.
  • the present invention describes a process of obtaining an antibody composition comprising a higher percentage of afucosylated glycans.
  • the invention describes a cell culture process wherein the cells are cultured in a medium supplemented with galactose at specific osmolality and harvested on the 12 th day or at 50% viability.
  • the present invention describes a method for obtaining a glycoprotein composition comprising higher percentage of afucosylated glycans.
  • FIG. 1 is an illustration of viable cell count as described in Example 1 .
  • FIG. 2 is an illustration of major glycoforms of glycoproteins as described in Example 1 .
  • glycocan refers to a monosaccharide or polysaccharide moiety.
  • glycoform or "glycovariant” have been used interchangeably herein, and refers to various oligosaccharide entities or moieties linked in their entirety to the Asparagine 297 (as per Kabat numbering) of the human Fc region of the glycoprotein in question, co translationally or post translationally within a host cell.
  • the glycan moieties that may be added during protein glycosylation include M3, M4, M5-8, M3NAG etc. Examples of such glycans and their structures are listed in Table 1 . However, Table 1 may in no way be considered to limit the scope of this invention to these glycans.
  • glycoform composition or “distribution” as used herein pertains to the quantity or percentage of different glycoforms present in a glycoprotein.
  • glycoprotein refers to protein or polypeptide having at least one glycan moiety.
  • glycoprotein any polypeptide attached to a saccharide moiety is termed as glycoprotein.
  • GO as used herein refers to protein glycan not containing galactose at the terminal end of the glycan chain.
  • Total afucosylated glycans described here, consists of glycan moieties wherein fucose is not linked to the non reducing end of N-acetlyglucosamine.
  • examples of afucosylated glycans include GO, G1 A, G1 B, G2, M3-M9NAG, M3-M9.
  • osmolality as used herein is defined as a measure of the osmoles of solute per kilogram of solvent (mOsm/kg) and may include ionized or non-ionized molecules. The osmolality may change during the cell culture process for e.g. by addition of feed, salts, additives or metabolites.
  • Table I Representative table of various glycans
  • temperature shift is defined as the change in temperature during the cell culture process.
  • the initial temperature of the cell culture process is higher than the final temperature i.e. cells are subjected to a temperature downshift wherein cells are first cultured at a higher temperature for certain time period after which temperature is reduced, and cells are cultured at this lower temperature for a fixed period of time
  • IVCC or “Integral viable cell concentration” refers to cell growth over time or integral of viable cells with respect to culture time that is used for calibration of specific protein production.
  • the integral of viable cell concentration can be increased either by increasing the viable cell concentration or by
  • the viable cell concentration or cell viability is defined as number of live cells in the total cell population.
  • the present invention discloses a cell culture method for obtaining a glycoprotein composition comprising increased percentage of afucosylated glycoforms.
  • the present invention provides a process for obtaining a glycoprotein composition comprising about 14% to about 18% of total afucosylated glycans comprising, culturing cells expressing said glycoprotein in a cell culture media a) comprising galactose
  • the glycoprotein comprises about 14.0% of total afucosylated glycans.
  • the glycoprotein comprises about 1 6.0% of total afucosylated glycans. In yet another embodiment the glycoprotein comprises about 18.0% of total afucosylated glycans.
  • the method may additionally be accompanied by culturing cells at first temperature for a first period of time and then subjecting cells to a second temperature for a second period of time.
  • the process comprises culturing cells at a first temperature of about 35 °C -37°C for about 72 hours, followed by lowering of temperature by about 2°C -7°C and harvesting cells on 12 th day or at about 50% viability, whichever is early.
  • the process comprises culturing cells at about 37°C for about 72 hours, followed by culturing cells at 33 °C and harvesting cells on 12 th day or about 50% viability whichever is earlier.
  • the cell culture media comprises galactose.
  • concentration of galactose for the purpose of the invention is about 6g/L.
  • the cell culture media that are useful in the application include but are not limited to, the commercially available products PF CHO (HyClone ® ), PowerCHO ® 2 (Lonza), Zap-CHO (Invitria), CD CHO, CDOptiCHOTM and CHO-S-SFMII
  • the method may additionally be accompanied by the addition of feed.
  • the feed is composed of nutrients or other medium components that have been depleted or metabolized by the cells.
  • the feed may include hormones, growth factors, ions, vitamins, nucleoside, nucleotides, trace elements, amino acids, lipids or glucose. These supplementary components may be added at one time or in series of additions to replenish.
  • feed may be a solution of depleted nutrient(s), mixture of nutrient(s) or a mixture of cell culture medium/feed providing such nutrient(s).
  • the feed may include, but are not limited to:
  • An anti-CD20 antibody was cloned and expressed in a CHO cell line as described in U.S. Patent No. 7381560 which is incorporated herein by reference.
  • rCHO cells expressing antibody at a seeding density of 0.4-0.6 million cells/ml are seeded in PF CHO (HyClone®, Catalog no: SH30335 & SH30334) at an osmolality of 320-340mOsm/Kg at 37°C and pH 7.05, supplemented with 6g/L galactose.
  • the cells are cultured for 3 hrs after which profile feeding of Feed lis done till 72 hrs. At 72 hrs, temperature is lowered to 33°C and simultaneously bolus Feed His added.
  • the culture is finally harvested after 180-288 hrs or at greater than 50% viability and the resulting antibody yield is determined.
  • the disclosed process was used to produce three batches of the anti-CD20 antibody (I -III).
  • the % viability, IVCC and antibody titer are shown in Table II I while % afucosylation is disclosed in Table IV.
  • Table III %Viability of cells, IVCC and antibody titer of cells at harvest

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention describes a cell culture process for obtaining a glycoprotein with the enhanced afucosylation content. The method involves culturing cells in a medium supplemented with galactose, at a specific osmolality, and harvesting on about 12th day or at about 50% viability to obtain glycoform composition with enhanced afucosylation.

Description

PROCESS OF OBTAINING GLYCOPROTEIN COMPOSITION WITH INCREASED AFUCOSYLATION CONTENT
RELATED APPLICATION
This application is related to and takes priority from Indian Provisional Application 332/CHE/2012 filed 30 Jan 2012 and is herein incorporated in its entirety.
INTRODUCTION
The invention describes a method for production of glycoprotein with increased afucosylation content. More specifically, the invention describes a cell culture process wherein cells are cultured in a medium supplemented with galactose, at a specific osmolality, and harvested on about 12th day or at about 50% viability to obtain glycoform composition with enhanced afucosylation.
Protein glycosylation is one of the most important post-translation
modifications associated with eukaryotic proteins. The two major types of glycosylation in eukaryotic cells are N-linked glycosylation, in which glycans are attached to the asparagine of the recognition sequence Asn-X-Thr/Ser, where "X" is any amino acid except proline, and O-linked glycosylation in which glycans are attached to serine or threonine. N-linked glycans further are of two types - high mannose type consisting of two N-acetylglucosamines plus a large number of mannose residues (more than 4), and the complex type that contain more than two N-acetylglucosamines plus any number of other types of sugars. In both N- and O- glycosylation, there is normally a range of glycan structures associated with each site (microheterogeneity). Macroheterogeneity results from the fact that not all N- glycan or O- glycan consensus sequences (Asn-X-Ser/Thr for N-glycan and serine or threonine for O-glycan present in the glycoproteins) are actually glycosylated. This may be consequence of the competitive action of diverse enzymes involved during glycosylation and are key to understanding glycoprotein heterogeneity (Marino K. et al., Nature Chemical Biology, 2010, Vol. 6, No. 10, pages 713 to723).
The process of N-linked glycosylation begins co-translationally in the endoplasmic reticulum (ER) where a complex set of reactions result in the attachment of Glc3NAc2Man9 (3 glucose, 2 N-acetylglucosamine and 9 mannose) to a carrier molecule called dolichol, and that is then transferred to the appropriate position (Asn297) on the polypeptide chain (Schwarz F. and Aebi M., Current Opinion in Structural Biology, 2011, Vol.21, Issue 5, pages 576 to 582 and Burda P., and Aebi M.,Biochemica et Biophysica acta (BBA) General Subjects, 1999, Volume 1426, Issue 2, pages 239 to 257).
The glycan complex formed in the ER lumen is further modified by action of enzymes in the Golgi apparatus. If the saccharide is relatively inaccessible, it is likely to remain in the original high-mannose form. If it is accessible, then several mannose residues may be cleaved and the saccharide further modified, resulting in the complex type N-glycans structure. In the c/'s-Golgi, mannosidase-1 may act to cleave/hydrolyzes a high mannose glycan, while further on,fucosyltransferase FUT- 8 fucosylates the glycan in the medial-Go\g\ (Harue Imai-Nishiya et al, BMC Biotechnology, 2007, 7:84).
Thus the sugar composition as well as the structural configuration of a glycan structure depends on the protein being glycosylated, the cells/cell lines, the glycosylation machinery in the Endoplasmic Reticulum and the Golgi apparatus, the accessibility of the machinery enzymes to the glycan structure, the order of action of each enzyme and the stage at which the protein is released from the
glycosylation machinery. In addition to the "in vivo" factors listed above, "external factors" may also affect the glycan structure and composition of a protein. These include the conditions in which the cell line expressing the protein is cultured, such as the medium composition, the composition and timing of the feed, osmolality, pH, temperature etc. There is a significant variability observed in terminal galactosylation that is dependent on the medium. It has been shown that feeding cultures with galactose up to a concentration 36mM results in high levels of galactosylation (Davies, J.; Jiang, L.; Pan, L.Z.; LaBarre, M. J.; Anderson, D.; Reff, M. Biotechnol.Bioeng. 2001, Vol.74, Issue 4pages 288 to 294). However in a separate study it was shown that galactose feeding does not affect the sialic acid content. Pacis et al has shown that higher osmolality may result in increase in the number of Man5 residues on recombinant antibodies, with a simultaneous reduction in G0F and G-| F glycoforms, resulting in its faster clearance from the body and thereby reducing its efficacy (Pacis E., Yu, M., Autsen, J., Bayer, R., Li F., Bitechnol Bioeng, 2011, Vol. 108, IssueW, pages 2348 to 2358).
The studies by Kaufman et al and Yoon et a/ show a reduction in protein sialylation upon decrease in temperature {Kaufman, H., Mazur X., Fussenegger, M., Bailey, J.E., Biotechnology and Bioengineering., 1999, Vol. 63, Issue 5, pages 573 to 582;Trummer, E., Fauland, K., et.ai, Biotechnol Bioeng., 2006, Vol. 94, Issue 6, pages 1045 to 1052 andYoon S.K., Song, J. Y., Lee, G.M., Biotechnol Bioeng., 2003, Vol. 82, Issue 3, pages 289 to 298). Further, reducing temperature can increase overall protein production by prolonging cell viability, which should, in principle, improve glycosylation (Moore A, Mercer J, Dutina G, Donahue CJ, Bauer KD,Mather JP, Etchverry T, Ryll T. Cytotechnology, 1997, Vol.23, pages 47 to 54). Likewise Borys et al has shown that a deviation from optimum pH results in decrease in the expression rate as well as the extent of glycosylation of proteins {Borys M.C., Linzer, D.I.H., Papoutsakis 1993, ΒΙΟ/technology, Vol.1 Ί , pages 720 to 724). The culture pH of a hybridoma cell line has been shown to affect the resulting galactosylation and sialylation of the monoclonal antibody (Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter- Katalinic J., Biotechnol Bioeng. 2003, Vol.83, Issue 3, pages 321 to 334).
Most of the therapeutic monoclonal antibodies (rMAb) that have been licensed and developed as medical agents are of the human lgG1 isotype. The effectiveness of these antibodies is dependent on sensitization of target cells for subsequent killing by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mediated through the interaction of the Fc with FcyRs receptors or complement respectively (Jefferis, R. Expert Opinion on Biological Therapy, 2007, Vol.7, Number 9, pages 1401 to 1413;Shields, R. L. et al., The Journal of Biological Chemistry, 2002, Vol.277 (30), pages 26733 to 26740; Shinkawa, T. et al. The Journal of Biological Chemistry, 2003, Vol.278 (5), pages 3466 to 3473;Niwa, R. et al. Journal of Immunological Methods, 2005, Vol.306, Issues 1-2, pages 151 to 160;Ferrara, C. et al., Biotechnol. Bioeng., 2006, Vol. 93, Issue 5, pages 851 to 861andKrapp, S. et ai, J. Mol. Biol., 2003, Vol. 325, pages 979 to 989). Further, the binding to the FcylM receptor is dependent on the fucose content of the Fc glycans wherein a reduction in fucose can increase effector function. Fucose-deficient IgGI s have shown a significant enhancement of ADCC up to 100-fold (Mori K., Cytotechnology, 2007, Vol. 55(2-3), pages 109 to 114& Shields RL, The Journal of Biological Chemistry, 2002, Vol. 277(30), pages 26733to 26740). Hence, non-fucosylated antibodies may be the promising next- generation therapeutic antibodies with improved efficacy and reduced dose based toxicities.
Robust stable production of completely non-fucosylated therapeutic antibodies consistent inquality has been achieved by the generation of a unique host cell line, in which the endogenous a-1 ,6-fucosyltransferase (FUT8) gene is knocked out. Further, antibodies with high oligomannose content having high affinity for FCYRI I IA, which is a key to high ADCC activity have been generated using specific inhibitors for e.g. kifunesine (Shen, A., Ng, D., Joly, J., Snedecor, B., Lu, Y., Meng, G., Nakamura, G., and Krummen, L. Metabolic engineering to control glycosylation,in cell culture and upstream processing (ed M. butler) 2007, Taylor and Francis group). Antibodies with the altered glycoform profiles have been produced using glycosylation enzyme mutants/knockouts or by using glycosylation inhibitors in cell culture medium such as deoxymannojirimycin (J Bischoff J., Liscum L., and Kornfeld R., The Journal of Biological Chemistry, 1986, Vol. 261(10), pages 4766 to 4774). However, the prior art lack in describing a cell culture process or modifications in process parameters to modify afucosylated glycan content in a glycoprotein composition. The present invention describes a process of obtaining an antibody composition comprising a higher percentage of afucosylated glycans. In particular the invention describes a cell culture process wherein the cells are cultured in a medium supplemented with galactose at specific osmolality and harvested on the 12th day or at 50% viability. SUMMARY
The present invention describes a method for obtaining a glycoprotein composition comprising higher percentage of afucosylated glycans. BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an illustration of viable cell count as described in Example 1 .
FIG. 2 is an illustration of major glycoforms of glycoproteins as described in Example 1 . DETAILED DESCRIPTION
Definitions
The term "glycan" refers to a monosaccharide or polysaccharide moiety.
The term "glycoform" or "glycovariant" have been used interchangeably herein, and refers to various oligosaccharide entities or moieties linked in their entirety to the Asparagine 297 (as per Kabat numbering) of the human Fc region of the glycoprotein in question, co translationally or post translationally within a host cell. The glycan moieties that may be added during protein glycosylation include M3, M4, M5-8, M3NAG etc. Examples of such glycans and their structures are listed in Table 1 . However, Table 1 may in no way be considered to limit the scope of this invention to these glycans.
The "glycoform composition" or "distribution" as used herein pertains to the quantity or percentage of different glycoforms present in a glycoprotein.
The term "glycoprotein" refers to protein or polypeptide having at least one glycan moiety. Thus, any polypeptide attached to a saccharide moiety is termed as glycoprotein.
GO as used herein refers to protein glycan not containing galactose at the terminal end of the glycan chain.
"Total afucosylated glycans" described here, consists of glycan moieties wherein fucose is not linked to the non reducing end of N-acetlyglucosamine.
Without limitation, examples of afucosylated glycans include GO, G1 A, G1 B, G2, M3-M9NAG, M3-M9.
The term "osmolality" as used herein is defined as a measure of the osmoles of solute per kilogram of solvent (mOsm/kg) and may include ionized or non-ionized molecules. The osmolality may change during the cell culture process for e.g. by addition of feed, salts, additives or metabolites.
Table I : Representative table of various glycans
Figure imgf000007_0001
The term "temperature shift" as used herein is defined as the change in temperature during the cell culture process. For the purpose of this invention, the initial temperature of the cell culture process is higher than the final temperature i.e. cells are subjected to a temperature downshift wherein cells are first cultured at a higher temperature for certain time period after which temperature is reduced, and cells are cultured at this lower temperature for a fixed period of time
As used herein, "IVCC" or "Integral viable cell concentration" refers to cell growth over time or integral of viable cells with respect to culture time that is used for calibration of specific protein production. The integral of viable cell concentration can be increased either by increasing the viable cell concentration or by
lengthening the process time.
The viable cell concentration or cell viability is defined as number of live cells in the total cell population.
The present invention discloses a cell culture method for obtaining a glycoprotein composition comprising increased percentage of afucosylated glycoforms.
In one embodiment, the present invention provides a process for obtaining a glycoprotein composition comprising about 14% to about 18% of total afucosylated glycans comprising, culturing cells expressing said glycoprotein in a cell culture media a) comprising galactose
b) at an osmolality of about 310 mOsm to about 340 mOsm c) at a first temperature for a first period of time
d) at a second temperature for a second period of time and
harvesting cells on about 12th day or about 50% viability,
In an embodi ment the glycoprotein comprises about 14.0% of total afucosylated glycans.
In another embodiment the glycoprotein comprises about 1 6.0% of total afucosylated glycans. In yet another embodiment the glycoprotein comprises about 18.0% of total afucosylated glycans.
Various methods described in the art such as Wuhrer et. al., Ruhaak L.R., and Geoffrey et. al. can be used for assessing glycovariants present in a glycoprotein composition(Wuhrer M. et al., Journal of Chromatography B, 2005, Vol.825, Issue 2, pages 124-133; Ruhaak L.R., Anal Bioanal Chem, 2010, Vol. 397:3457-3481 andGeoffrey, R. G. et. al. Analytical Biochemistry 1996, Vol. 240, pages 210-226).
In one aspect of the invention, the method may additionally be accompanied by culturing cells at first temperature for a first period of time and then subjecting cells to a second temperature for a second period of time.
In yet another embodiment of the invention, the process comprises culturing cells at a first temperature of about 35 °C -37°C for about 72 hours, followed by lowering of temperature by about 2°C -7°C and harvesting cells on 12th day or at about 50% viability, whichever is early.
In yet another embodiment of the invention, the process comprises culturing cells at about 37°C for about 72 hours, followed by culturing cells at 33 °C and harvesting cells on 12th day or about 50% viability whichever is earlier.
In one aspect of the invention, the cell culture media comprises galactose. The concentration of galactose for the purpose of the invention is about 6g/L.
The cell culture media that are useful in the application include but are not limited to, the commercially available products PF CHO (HyClone®), PowerCHO® 2 (Lonza), Zap-CHO (Invitria), CD CHO, CDOptiCHO™ and CHO-S-SFMII
(Invitrogen), ProCHO™ (Lonza), CDM4CHO™ (Hyclone), DMEM (Invitrogen), DMEM/F12 (Invitrogen), Ham's F10 (Sigma), Minimal Essential Media (Sigma), and RPMI -1 640 (Sigma).
In one aspect of the invention, the method may additionally be accompanied by the addition of feed. The feed is composed of nutrients or other medium components that have been depleted or metabolized by the cells. The feed may include hormones, growth factors, ions, vitamins, nucleoside, nucleotides, trace elements, amino acids, lipids or glucose. These supplementary components may be added at one time or in series of additions to replenish. Thus feed may be a solution of depleted nutrient(s), mixture of nutrient(s) or a mixture of cell culture medium/feed providing such nutrient(s).
The feed may include, but are not limited to:
Table II : Representative feeds and feed composition
Figure imgf000010_0001
Specific embodiment of the invention is more fully defined by reference to the following example. This example should not, however, be construed as limiting the scope of the invention.
Example I
An anti-CD20 antibody was cloned and expressed in a CHO cell line as described in U.S. Patent No. 7381560 which is incorporated herein by reference. rCHO cells expressing antibody at a seeding density of 0.4-0.6 million cells/ml are seeded in PF CHO (HyClone®, Catalog no: SH30335 & SH30334) at an osmolality of 320-340mOsm/Kg at 37°C and pH 7.05, supplemented with 6g/L galactose. The cells are cultured for 3 hrs after which profile feeding of Feed lis done till 72 hrs. At 72 hrs, temperature is lowered to 33°C and simultaneously bolus Feed His added. The culture is finally harvested after 180-288 hrs or at greater than 50% viability and the resulting antibody yield is determined. The disclosed process was used to produce three batches of the anti-CD20 antibody (I -III). The % viability, IVCC and antibody titer are shown in Table II I while % afucosylation is disclosed in Table IV. The viable cell count and the glycan profileare disclosed in Figures 1 -2.
Table III : %Viability of cells, IVCC and antibody titer of cells at harvest
Figure imgf000011_0001
Table IV: % Total Afucosylation of the antibody
Figure imgf000011_0002

Claims

CLAIMS We claim:
1 . A cell culture process for obtaining a glycoprotein composition comprising about 14% to about 18% total afucosylated glycans comprising culturing cells expressing said glycoprotein in a cell culture media
a) comprising galactose
b) seeding cells at an osmolality of about 31 OmOsm/Kg to about 340mOsm/Kg
c) at a first temperature for a first period of time
d) at a second temperature for a second period of time and harvesting cells on about 12th day or about 50% viability.
2. A process according to claim 1 , wherein the said glycoprotein comprises about 14% total afucosylated glycans.
3. A process according to claim 1 , wherein the said glycoprotein comprises about 16% total afucosylated glycans.
4. A process according to claim 1 , wherein the said glycoprotein comprises about 18% total afucosylated glycans.
5. A process according to claim 1 , wherein cells are cultured in a cell culture media comprising about 6 g/L galactose.
6. A process according to claim 1 , wherein cells are cultured in step c) at a temperature of about 35QC to about 37QC.
7. A process according to claim 1 , wherein cells are cultured in step c) at a temperature of about 37QC.
8. A process according to claim 1 , wherein cells are cultured in step d) at a temperature reduced in a range of 2- 7QC.
9. A process according to claim 1 , wherein cells are cultured in step d) at a temperature of about 33QC.
10. A process according to claim 1 , wherein the process further comprises addition of feed.
PCT/IB2012/057091 2012-01-30 2012-12-08 Process of obtaining glycoprotein composition with increased afucosylation content WO2013114165A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN332/CHE/2012 2012-01-30
IN332CH2012 2012-01-30

Publications (1)

Publication Number Publication Date
WO2013114165A1 true WO2013114165A1 (en) 2013-08-08

Family

ID=48904474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/057091 WO2013114165A1 (en) 2012-01-30 2012-12-08 Process of obtaining glycoprotein composition with increased afucosylation content

Country Status (1)

Country Link
WO (1) WO2013114165A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
WO2017120347A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US10590455B2 (en) 2014-02-25 2020-03-17 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1762383A (en) * 2005-10-12 2006-04-26 郭斌阁 Preparation process of hepatic cell growth promotion protein and its injection preparation method
CN1820080A (en) * 2002-12-23 2006-08-16 布里斯托尔-迈尔斯斯奎布公司 Product quality enhancement in mammalian cell culture processes for protein production
CN1850974A (en) * 2005-04-21 2006-10-25 李宁 Human alpha-lacto albumin gene transgenic cloned macro domectic animal production method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1820080A (en) * 2002-12-23 2006-08-16 布里斯托尔-迈尔斯斯奎布公司 Product quality enhancement in mammalian cell culture processes for protein production
CN1850974A (en) * 2005-04-21 2006-10-25 李宁 Human alpha-lacto albumin gene transgenic cloned macro domectic animal production method
CN1762383A (en) * 2005-10-12 2006-04-26 郭斌阁 Preparation process of hepatic cell growth promotion protein and its injection preparation method

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US10590455B2 (en) 2014-02-25 2020-03-17 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2017120359A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
WO2017120347A1 (en) * 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
CN109153716A (en) * 2016-01-06 2019-01-04 安口生物公司 Adjust the non-fucosylation species in monoclonal antibody combination
US11285210B2 (en) 2016-02-03 2022-03-29 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability

Similar Documents

Publication Publication Date Title
WO2013114164A1 (en) Method for obtaining glycoprotein composition with increased afucosylation content
US10059770B2 (en) Process of modulating man5 and/or afucosylation content of a glycoprotein composition
Wang et al. Antibody glycoengineering strategies in mammalian cells
Costa et al. Glycosylation: impact, control and improvement during therapeutic protein production
Mastrangeli et al. The formidable challenge of controlling high mannose-type N-glycans in therapeutic mAbs
WO2013114167A1 (en) Process of obtaining glycoform composition
Liu et al. The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody
US10144944B2 (en) Methods of cell culture
Batra et al. Glycosylation of monoclonal antibody products: Current status and future prospects
Aghamohseni et al. Effects of nutrient levels and average culture pH on the glycosylation pattern of camelid-humanized monoclonal antibody
WO2013114165A1 (en) Process of obtaining glycoprotein composition with increased afucosylation content
WO2015140700A1 (en) Cell culture process
Heffner et al. Glycoengineering of mammalian expression systems on a cellular level
CN113272440B (en) Methods for altering the glycosylation profile of a recombinant glycoprotein produced in cell culture
EP3127917B1 (en) Method for preparing antibody through regulation of sugar content of antibody
WO2015128793A1 (en) A process for modifying high mannose and galactosylation content of a glycoprotein composition
Wang et al. Strategies for engineering protein N-glycosylation pathways in mammalian cells
Olivier et al. EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity
Spearman et al. The role of glycosylation in therapeutic antibodies
Seo et al. Effect of glucose feeding on the glycosylation quality of antibody produced by a human cell line, F2N78, in fed-batch culture
US10590455B2 (en) Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
US20240376211A1 (en) A process to produce a pharmaceutical composition
Spearman et al. Glycosylation in cell culture
WO2014170866A2 (en) Process of obtaining glycoprotein composition with increased galactosylation content
del Val et al. Application of quality by design paradigm to the manufacture of protein therapeutics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12867121

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12867121

Country of ref document: EP

Kind code of ref document: A1